Menu Search
Equities

LivaNova PLC

LIVN:NSQ

LivaNova PLC

Actions
Health CareMedical Equipment and Services
  • Price (USD)51.32
  • Today's Change-0.38 / -0.74%
  • Shares traded400.59k
  • 1 Year change+16.50%
  • Beta0.9820
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform4
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for LivaNova PLC have a median target of 71.00, with a high estimate of 90.00 and a low estimate of 60.00. The median estimate represents a 37.33% increase from the last price of 51.70.
High74.1%90.00
Med37.3%71.00
Low16.1%60.00

Earnings history & estimates in USD

On Oct 30, 2024, LivaNova PLC reported 3rd quarter 2024 earnings of 0.90 per share. This result exceeded the 0.72 consensus of the 9 analysts covering the company and exceeded last year's 3rd quarter results by 23.29%.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+6.81%
LivaNova PLC reported annual 2023 earnings of 2.80 per share on Feb 21, 2024.
Average growth rate+9.21%
More ▼

Revenue history & estimates in USD

LivaNova PLC had 3rd quarter 2024 revenues of 318.10m. This bettered the 300.49m consensus of the 8 analysts covering the company. This was 20.77% above the prior year's 3rd quarter results.
Average growth rate+2.84%
LivaNova PLC had revenues for the full year 2023 of 1.15bn. This was 12.89% above the prior year's results.
Average growth rate+2.14%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.